BlossomHill Therapeutics Announces Updated SOLARA Trial Data (BH-30643)

What Happened

• BlossomHill Therapeutics (BLSM) announced on September 15, 2026 (Regulation FD disclosure, Item 7.01) updated clinical data from its ongoing Phase 1/2 SOLARA trial of BH-30643 in non‑small cell lung cancer (NSCLC) patients who have secondary EGFR resistance mutations such as EGFR C797S. The data were highlighted in a mini‑oral presentation at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea. The company furnished the press release announcing this update as Exhibit 99.1 to the 8‑K.

Key Details

• Drug: BH-30643 (BlossomHill's investigational therapy).
• Trial: Phase 1/2 SOLARA (ongoing), focusing on NSCLC patients with secondary EGFR resistance mutations (e.g., EGFR C797S).
• Announcement date: September 15, 2026; presentation venue: IASLC 2026 World Conference on Lung Cancer, Seoul.
• Disclosure type: Regulation FD press release filed on Form 8‑K (Exhibit 99.1).

Why It Matters

• This filing signals a clinical update for one of BlossomHill’s lead programs; investors often watch Phase 1/2 data for signs of safety and early activity that can affect the company’s development timeline and valuation. The Regulation FD disclosure and conference presentation mean the information was released publicly to the market. Review the company’s full press release and future trial updates for specifics on safety, efficacy measures, and next steps before making investment decisions.